Literature DB >> 8687122

Induction of Ley antigen by 5-aza-2'-deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells.

T Yamada1, S Ohwada, F Saitoh, M Adachi, Y Morishita, M Hozumi.   

Abstract

We investigated the effect of 5-aza-2'-deoxycytidine (ADC) (a specific inhibitor of DNA methylation) on differentiation, Lewisy (Ley) antigen expression, and DNA fragmentation (a biochemical marker of apoptosis) in human pancreatic cancer MIA PaCa-2 cells. ADC markedly inhibited the growth of MIA PaCa-2 cells. Flow cytometric analysis showed that ADC suppressed the cell population in the G1 phase, but enhanced it in the G2/M phase. On the other hand, several markers of cell differentiation including morphological and biochemical alterations were distinctly induced in cells treated with ADC. Morphologically, the cells were enlarged and thinner than the untreated control cells, and intracellular alkaline phosphatase (ALP) activity was markedly increased. Additionally, biochemical markers of apoptosis including DNA fragmentation and Ley antigen expression were induced in association with the appearance of morphological and biochemical markers of differentiation (ALP). These results suggest that the hypomethylation of DNA is involved in the molecular mechanism of growth inhibition, induction of apoptosis, and differentiation in human pancreatic cancer MIA PaCa-2 cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687122

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen.

Authors:  Somdutta Saha; Ramachandran Murali; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-10

Review 2.  Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries.

Authors:  Patompon Wongtrakoongate
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

3.  A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.

Authors:  Davendra Sohal; Smitha Krishnamurthi; Rita Tohme; Xiaorong Gu; Daniel Lindner; Terry H Landowski; John Pink; Tomas Radivoyevitch; Sherry Fada; Zhenghong Lee; Dale Shepard; Alok Khorana; Yogen Saunthararajah
Journal:  Am J Cancer Res       Date:  2020-09-01       Impact factor: 6.166

4.  A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells.

Authors:  Shiro Kohi; Norihiro Sato; Xiao-Bo Cheng; Atsuhiro Koga; Aiichiro Higure; Keiji Hirata
Journal:  Clin Exp Metastasis       Date:  2015-11-20       Impact factor: 5.150

5.  DNMT1 ablation suppresses tumorigenesis by inhibiting the self-renewal of esophageal cancer stem cells.

Authors:  Ying Teng; Xiying Yu; Hui Yuan; Liping Guo; Wei Jiang; Shih-Hsin Lu
Journal:  Oncotarget       Date:  2018-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.